company background image
AIM logo

AIM ImmunoTech NYSEAM:AIM Stock Report

Last Price

US$0.44

Market Cap

US$21.6m

7D

10.7%

1Y

4.0%

Updated

27 Mar, 2024

Data

Company Financials +

AIM Stock Overview

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.

AIM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AIM ImmunoTech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AIM ImmunoTech
Historical stock prices
Current Share PriceUS$0.44
52 Week HighUS$0.75
52 Week LowUS$0.32
Beta-0.12
1 Month Change8.05%
3 Month Change-8.09%
1 Year Change3.99%
3 Year Change-80.48%
5 Year Change-93.05%
Change since IPO-99.97%

Recent News & Updates

Recent updates

Here's Why We're Not Too Worried About AIM ImmunoTech's (NYSEMKT:AIM) Cash Burn Situation

Feb 28
Here's Why We're Not Too Worried About AIM ImmunoTech's (NYSEMKT:AIM) Cash Burn Situation

Shareholder Returns

AIMUS BiotechsUS Market
7D10.7%0.9%0.4%
1Y4.0%10.3%28.8%

Return vs Industry: AIM underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: AIM underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is AIM's price volatile compared to industry and market?
AIM volatility
AIM Average Weekly Movement11.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: AIM's share price has been volatile over the past 3 months.

Volatility Over Time: AIM's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
196623Thomas Equelshttps://aimimmuno.com

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

AIM ImmunoTech Inc. Fundamentals Summary

How do AIM ImmunoTech's earnings and revenue compare to its market cap?
AIM fundamental statistics
Market capUS$21.64m
Earnings (TTM)-US$20.77m
Revenue (TTM)US$193.00k

112.1x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AIM income statement (TTM)
RevenueUS$193.00k
Cost of RevenueUS$30.00k
Gross ProfitUS$163.00k
Other ExpensesUS$20.94m
Earnings-US$20.77m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 02, 2024

Earnings per share (EPS)-0.43
Gross Margin84.46%
Net Profit Margin-10,764.25%
Debt/Equity Ratio0%

How did AIM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.